HEPATOLOGY AND LIVER DISEASE: EXPLORING THE IMPACT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ON GLOBAL HEALTH
Main Article Content
Keywords
Non-Alcoholic Fatty Liver Disease, metabolic syndrome, diagnostic methods, obesity, global prevalence
Abstract
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common chronic liver disease in the world, occurring in about one-quarter of the population. It is closely linked with the components of metabolic syndrome, mainly obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia. Knowledge of the regional burden, diagnostic efficiency, and risk factors is important for tackling its impact on global health. Studies included gave human information regarding epidemiology, diagnostic methods, and metabolic correlations. The peer-reviewed literature was searched in PubMed, Scopus, and Web of Science for human studies published. Inclusion criteria needed prevalence data, diagnostic methods, or risk factor associations. The main variables of the study design, population characteristics, diagnostic technique, and clinical outcomes were obtained. Data were synthesised and statistically examined for sensitivity, specificity, and odds ratios. NAFLD prevalence varied between 13% in Africa and 32% in the Middle East. Liver biopsy was still the gold standard for the diagnosis (95% sensitivity, 98% specificity), but Magnetic Resonance Imaging–Proton Density Fat Fraction (MRI-PDFF) and FibroScan provided accurate non-invasive options. Obesity presented the highest odds ratio (3.5), followed by T2DM (2.8), high-fat diet (2.2), PNPLA3 gene variant (1.9), and gut dysbiosis (1.7), all statistically significant. NAFLD is a significant public health burden with substantial regional variation. Reliable, non-invasive diagnosis and focused intervention strategies are crucial to stem its progression and minimise global disease burden.
References
2. Anderson, E. L., Howe, L. D., Jones, H. E., Higgins, J. P., Lawlor, D. A., & Fraser, A. (2015). The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PloS one, 10(10), e0140908.
3. Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., ... & Younossi, Z. (2022). American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice, 28(5), 528-562.
4. Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., ... & George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of hepatology, 73(1), 202-209.
5. Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J., ... & Razavi, H. (2018). Modelling NAFLD disease burden in China, France, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030. Journal of hepatology, 69(4), 896-904.
6. Gish, R., Fan, J. G., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M., & Boursier, J. (2024). Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Hepatology International, 18(Suppl 2), 977-989.
7. Gofton, C., & George, J. (2021). Updates in fatty liver disease: Pathophysiology, diagnosis and management. Australian Journal of General Practice, 50(10), 702-707.
8. Hoozemans, J., de Brauw, M., Nieuwdorp, M., & Gerdes, V. (2021). Gut microbiome and metabolites in patients with NAFLD and after bariatric surgery: a comprehensive review. Metabolites, 11(6), 353.
9. Josloff, K., Beiriger, J., Khan, A., Gawel, R. J., Kirby, R. S., Kendrick, A. D., ... & Halegoua-DeMarzio, D. (2022). Comprehensive review of cardiovascular disease risk in nonalcoholic fatty liver disease. Journal of Cardiovascular Development and Disease, 9(12), 419.
10. Luukkonen, P. K., Porthan, K., Ahlholm, N., Rosqvist, F., Dufour, S., Zhang, X. M., ... & Yki-Järvinen, H. (2023). The PNPLA3 I148M variant increases ketogenesis and decreases hepatic de novo lipogenesis and mitochondrial function in humans. Cell Metabolism, 35(11), 1887-1896.
11. Nakajima, R., Sekiya, M., Furuta, Y., Miyamoto, T., Sato, M., Fukuda, K., ... & Shimano, H. (2022). A case of NASH with genetic predisposition successfully treated with an SGLT2 inhibitor: a possible involvement of mitochondrial dysfunction. Endocrinology, Diabetes & Metabolism Case Reports, 2022(1).
12. Pal, S. C., Eslam, M., & Mendez-Sanchez, N. (2022). Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones, 21(4), 573-589.
13. Singal, A. G., & El-Serag, H. B. (2015). Hepatocellular carcinoma from epidemiology to prevention: translating knowledge into practice. Clinical gastroenterology and hepatology, 13 (12), 2140-2151.
14. Softic, S., Cohen, D. E., & Kahn, C. R. (2016). Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Digestive diseases and sciences, 61, 1282-1293.
15. Stefan, N., Schick, F., Birkenfeld, A. L., Häring, H. U., & White, M. F. (2023). The role of hepatokines in NAFLD. Cell metabolism, 35(2), 236-252.
16. Stefan, N., Yki-Järvinen, H., & Neuschwander-Tetri, B. A. (2024). Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. The Lancet Diabetes & Endocrinology.
17. Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., ... & Floria, M. (2020). The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD). Journal of diabetes research, 2020(1), 3920196.
18. Targher, G., Byrne, C. D., & Tilg, H. (2020). NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut, 69(9), 1691-1705.
19. Tsamos, G., Kalopitas, G., Evripidou, K., Vasdeki, D., Koufakis, T., Kanavas, V., ... & Chourdakis, M. (2024). The effects of olive oil consumption on biochemical parameters and body mass index of people with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Nutrients, 16(6), 857.
20. Ub, V., Ks, K., & Pu, V. (2024). Development of multi-particulate formulation of glabridin with L-phenylalanine and its pre-clinical evaluation for anti-obesity activity. International Journal of Drug Delivery Technology, 14(1), 183–187. https://doi.org/10.25258/ijddt.14.1.27
21. Uthayakumar, C., & Kotalawala, S. (2021). Impact of Obesity in Non-Alcoholic Fatty Liver Disease. Journal of Biomedical Science and Engineering, 14(2), 21-32.
22. Villard, A., Boursier, J., & Andriantsitohaina, R. (2021). Bacterial and eukaryotic extracellular vesicles and nonalcoholic fatty liver disease: new players in the gut-liver axis?. American Journal of Physiology-Gastrointestinal and Liver Physiology, 320(4), G485-G495.
23. Vos, M. B., Abrams, S. H., Barlow, S. E., Caprio, S., Daniels, S. R., Kohli, R., ... & Xanthakos, S. A. (2017). NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). Journal of pediatric gastroenterology and nutrition, 64(2), 319-334.
24. Younossi, Z., & Henry, L. (2020). The burden of NAFLD worldwide. Non-Alcoholic Fatty Liver Disease: A 360-degree Overview, 15-24.
25. Zito, R. (2024). Liver Transcriptome Analysis in NAFLD Patients.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sohom Ghosh
Assistant Professor, Jims Budge Budge,
Abhishek Mondal
Assistant Professor, JIMSH, BudgeBude,
Rohitaswa Mandal
Assistant Professor, JIMSH, BudgeBudge ,
Mainak Ranjan Baksi
Assistant Professor, JIMSH, BudgeBudge,
Santanu Mandal
Assistant Professor, JIMSH, BudgeBudge,